Clinical Trial Update: Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of nimotuzumab with cisplatin and docetaxel for advanced non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Biotech Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: WITHDRAWN